RECRUITING

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable. Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.

Official Title

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Quick Facts

Study Start:2024-01-02
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07030348

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Be at least 19 years old.
  2. 2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  3. 3. A biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).
  4. 4. Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.
  5. 1. Be at least 19 years old.
  6. 2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
  7. 3. Patients with pancreatic cystic tumors or patients with acute or chronic pancreatitis.
  8. 4. No evidence of a pancreatic disease.
  1. 1. Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.
  2. 2. Hemodynamically unstable and unable to have an endoscopy performed.
  3. 3. A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.
  4. 4. A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.

Contacts and Locations

Study Contact

HyeJin Song, CRC
CONTACT
+82-2-2045-3825
asangicrc@gmail.com

Study Locations (Sites)

University of Colorado Hospital
Aurora, Colorado, 80045
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States

Collaborators and Investigators

Sponsor: Do Hyun Park

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-01-02
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2024-01-02
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreatic Cancers
  • Pancreatic Diseases